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2FSG is a nonprofit consulting firm specializing in strategy, evaluation, and research. 
Our international teams work across all sectors by partnering with corporations, 
foundations, nonprofits, and governments in every region of the globe. Our goal is 
to help companies and organizations—individually and collectively—achieve greater 
social change.
Our approach is founded on the belief that corporations can create shared value 
by using their core capabilities in ways that contribute to both social progress and 
economic success. Working with many of the world’s leading corporations, nonprofit 
organizations, and charitable foundations, FSG has completed more than 400 
consulting engagements around the world, produced dozens of research reports, 
published influential articles in Harvard Business Review and Stanford Social Innovation 
Review, and has been featured in The New York Times, Wall Street Journal, Economist, 
Financial Times, BusinessWeek, Fast Company, Forbes, and on NPR, amongst others. 
Learn more about FSG at www.fsg.org
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2Pharmaceutical and medical 
device companies, the focus 
of this report, create both 
economic and societal value 
when they provide products 
that tackle important health 
problems. Not all fields have 
clear opportunities to create 
competitive advantage while 
simultaneously advancing such a vital societal goal as 
better health.  However, the opportunity for these indus-
tries to create shared value is far greater. 
Historically, pharmaceutical and medical device compa-
nies built their businesses by serving affluent markets 
in North America, Europe, and Japan. In the process, 
they have overlooked the unmet health needs of billions 
of underserved patients, and with it, huge opportunities 
for innovation and growth. 
Fortunately, there are promising signs of change. 
Some pharmaceutical and medical device companies 
are prioritizing previously underserved patients and 
markets. Rather than seeing efforts in assisting lower 
income customers as corporate social responsibility and 
philanthropy, companies are transforming their products, 
pricing, manufacturing, distribution, and marketing 
to profitably meet previously unmet needs. There are 
encouraging signs that serving these new markets can be 
profitable, and multiply the size of the available market.
Capitalism faces a watershed moment. 
Now is the time for the private sector to demonstrate 
its potential for both economic growth and societal 
purpose. As companies create shared value by meeting 
social needs, the capabilities and scalability of business 
is unleashed on societal challenges such as the rising 
burden of non-communicable diseases in the devel-
oping world. Government, local health systems, and the 
nonprofit sector will play leadership roles in prevention 
and treatment. But capitalism, guided by the pursuit of 
shared value, will take on a greater role in addressing 
the global burden of disease.
This report follows the January 2011 
release of the article “Creating Shared 
Value” in Harvard Business Review. 
It represents the first of a series of 
studies that will focus on shared value 
within particular sectors.1 The report 
seeks to inform and inspire companies 
in the pharmaceutical and medical 
device industries, while providing 
insights that can assist companies 
in other fields create and implement shared value. We 
hope that this study spurs leaders from the private 
sector, civil society, investors, and government in new 
approaches to addressing health problems through new 
management thinking, innovations in business models, 
and cross-sector collaboration. 
	CREATING SHARED VALUE
“Companies create shared value by creating economic value and 
societal value simultaneously. There are three distinct ways to do 
this: by reconceiving products and markets, redefining productivity 
in the value chain, and building supportive industry clusters at the 
company’s locations.”
  Michael E. Porter and Mark R. Kramer, “Creating Shared Value,” Harvard Business Review
Shared value is inherent in health technology companies.
By Michael E. Porter, Professor 
Harvard Business School and Co-Founder, FSG
Foreword
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Executive Summary
Increasingly, companies are seeing opportunities to 
meet the needs of underserved populations in low- 
and middle-income countries, where they once saw 
little commercial interest. This report highlights 
how pharmaceutical and medical device compa-
nies are creating shared value in global health by 
enhancing their competitiveness while simultane-
ously addressing the global burden of disease — often 
working in partnership with governments, funders, 
and nonprofit organizations.
Background
  In return for investing in risky R&D to develop 
revolutionary, life-saving technologies, society 
provides pharmaceutical and medical device firms 
with intellectual property protections that reward 
success. While this social contract has worked well 
for the world’s richest nations, until recently, the 
underserved in Asia, Africa, and Latin America 
have generally been an afterthought. Global health 
advocates have called for better adapted prod-
ucts and lower prices, to which companies have 
responded. But until recently, efforts have largely 
been philanthropic or reputation-driven. 
  In the last decade, this picture has begun to change. 
Developed markets are coming under pressure as 
traditional health systems are scrutinizing costs as 
never before. At the same time, R&D productivity 
has fallen, particularly for pharmaceutical firms. 
This is forcing companies to reconsider opportu-
nities in low- and middle-income countries they 
may previously have overlooked. In parallel, newly 
recognized market opportunities are emerging 
around the enormous unaddressed health needs in 
these countries. Emerging markets could account 
for nearly half of worldwide revenues for phar-
maceutical companies by 2012,2 and these areas 
are expected to account for 75 percent of industry 
growth over the coming decade.3
The	Shared	Value	Opportunity	
  Companies create shared value in global health 
when they compete on the basis of improving 
health outcomes for the underserved. Rather than 
competing for market share among well-funded 
payers and wealthy patients, companies view their 
success in terms of their ability to improve health 
outcomes by building and serving new markets. To 
achieve that success, companies need to systemati-
cally and relentlessly uncover new, unmet needs, 
and find new and better ways to address them at 
scale.
  Low- and middle-income countries have vast 
unmet needs. The top five non-injury causes of 
death in 2008 claimed nearly 29 million lives in 
low- and middle-income countries, compared with 
just 6.6 million in high-income countries. South-
east Asian and African countries, in particular, 
face a double burden of infectious diseases and 
non-communicable diseases (NCDs), such as 
cardiovascular disease, diabetes, and cancer. 
  Meeting these needs is challenging, even for 
sophisticated corporations. Missing skills and 
knowledge, limited market information, ineffective 
regulation, inadequate health systems, and limited 
funding or inability of patients to pay present firms 
with huge barriers to entry. To overcome these 
barriers, companies are investing in three levels of 
shared value (see Figure 1).
  Efforts to create shared value across the three 
levels are mutually reinforcing. Productive and 
lower-cost value chains are essential to introducing 
redesigned product portfolios to underserved 
A new dynamic is changing the basis of competition in the 
pharmaceutical and medical device industries.
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markets. Strong clusters can enable firms to serve 
population segments that were previously out of 
reach, and can open up new, lower-cost manu-
facturing and distribution options. Leading firms 
are beginning to design multi-level approaches 
to harness this multiplier effect, though the right 
combination will be unique to a particular company 
and market.
  Stakeholders and shareholders are warming to 
shared value. Global health stakeholders desire 
a move away from charity to more sustainable 
and scalable ways to provide drugs, vaccines, 
and medical devices to patients in underserved 
markets. And these stakeholders want to partner 
— in a recent survey, 79 percent of nonprofit 
organizations reported that pharmaceutical and 
medical device companies are essential partners in 
the effort to achieve their missions.4 Mainstream 
investors are adopting a wait-and-see attitude to 
company engagement in low- and middle-income 
countries. More socially-minded investors and 
analysts are paying increasing attention to compa-
nies reaching the underserved.
  Shared value cannot address all global health needs. 
Systemic market failures exist in health technology, 
notably around neglected diseases, where needed 
products and services are not being developed or 
delivered on a commercial basis due to the inability 
of patients to pay. A shared value frontier defines 
the boundary of such failures.
  However, companies are innovating to serve 
patients at the shared value frontier, where health 
systems are notably deficient or patients lack 
the ability to pay. As local complexities increase, 
companies are employing sophisticated combina-
tions of shared value approaches. In the longer 
term, there is good evidence to believe that some 
companies will expand the shared value frontier 
further into poorer populations. 
  Corporate philanthropy and external funders, 
such as governments and foundations, can also 
bridge the shared value frontier. Corporate 
philanthropy can accelerate existing shared value 
initiatives — often through strengthening health 
systems — or incubate new projects in locations 
where companies do not have commercial opera-
tions. Governments and private funders also offer 
incentives that reduce risk for investments in R&D 
efforts or establish commitments for future drug or 
vaccine purchases.
Figure 1: Levels of Shared Value Creation for Pharmaceutical and Medical Device Companies
1 Reconceiving Products  and Markets 2 Redefining Productivity  in the Value Chain 3 Enabling Local Cluster  Development
•	 R&D	for	drugs,	vaccines,	and	
devices	that	fill	unmet	health	needs
•	 Adaptation	of	existing	products	to	
reduce	complexity	and	cost
•	 Tailored	product	offerings	to	meet	
local	market	conditions
•	 Collaborative	and	homegrown	R&D	
to	reduce	cost	and	risk
•	 Efficient,	local	supply	chains	
and	manufacturing	to	reduce	
production	costs
•	 Locally-adapted	sales	and	
distribution	to	penetrate	new	
markets	and	better	meet	patient	
needs
•	 Behavior-change	campaigns	to	
increase	the	sophistication	of	
demand	for	health	care
•	 Health	system	strengthening	to	
enable	delivery	of	needed	products	
and	services
•	 Advocacy	and	capacity	building	
to	strengthen	policy	and	the	
regulatory	environment
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Implementing	Shared	Value	for	Global	Health
Common success factors are emerging among companies as they implement shared value. Leading companies 
are following five principles:
  Focused	and	determined	leadership	at	the	CEO	
and	country	levels. Companies that excel at shared 
value have CEOs and country-level managers who 
bring a compelling vision and personal involvement 
to expansion efforts in low- and middle-income 
markets. Without leadership, pharmaceutical and 
medical device companies stumble and resort to 
more traditional, charity-led engagement with 
patients in low- and middle-income countries.
  A	culture	of	innovation	and	learning	reflected	
in	structures	and	incentives. Cross-functional 
teams can help to coalesce, prioritize, and coordi-
nate shared value approaches that straddle R&D, 
government affairs, and marketing. Companies 
have also created separate social innovation units 
that directly manage shared value initiatives.
  New	approaches	to	measurement	that	track	
the	link	between	business	value	and	improved	
patient	lives. Such metrics offer companies a 
way to understand what works to create shared 
value, and allows them to assess the potential of 
new investments, to allocate resources, and to set 
relevant incentives. While few companies have 
developed robust systems to measure shared value, 
early adopters are starting to use such information 
to make key management decisions, and are seeing 
improved performance as a result.
  New	skills	in	identifying	and	acting	on	unmet	
health	needs. To penetrate new markets, compa-
nies require employees with on-the-ground 
knowledge of health needs among underserved 
patients, an ability to translate needs into busi-
ness strategy, and strong stakeholder-engagement 
capabilities.
  New	partnerships	for	shared	value	insights	
and	implementation. Companies are looking to 
a new set of partners to help with shared value 
strategy-setting and specific competencies in 
adapting products, improving productivity and cost 
effectiveness, and strengthening the competitive 
context. Many of these partners are nonprofits, 
which marks a shift from prior roles as corporate 
philanthropic grantees. 
Executive Summary
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Catalyzing	Greater	Shared	Value	for	Global	Health	
The following recommendations for companies and stakeholders can catalyze greater experimentation in 
shared value for the benefit of companies, patients, and health systems.
Recommendations for Companies	
 → Shift from defensive to affirmative engagement with patients in low- and middle-income countries. 
Companies should be transparent with global stakeholders about their ambitions in low- and middle-
income countries. Specific shared value approaches, motivated by profit, can be articulated for the benefit of 
the global health field. Where shared value approaches are not presently feasible, companies can explain the 
role of their philanthropic contributions and the intentions of partnerships with government and private 
funders.
 → Innovate and capture knowledge on health product delivery.  
As companies learn more about how to market drugs, vaccines, and medical devices to the hard-to-reach 
and poorly-served populations, lessons should be shared, within the limits of competitive confidentiality. 
Promising multi-sector models for sharing best practices on health product distribution and disease 
awareness-building are emerging. 
 → Experiment with shared value measurement to spur learning and innovation.  
Pharmaceutical and medical device companies should be in a position to lead other industries on measuring 
shared value, due to the inherent alignment between the increased sales of their life-enhancing products 
and meeting patient health needs. Companies should set, specific, forward-looking targets for popula-
tions, behavior changes, health system strengthening and disease indicators, and should measure progress 
towards them. 
 → Invest early to gain first-mover advantage.  
Companies that invest ahead of their rivals, such as GlaxoSmithKline in India and Novo Nordisk in China, 
find themselves with a sizable competitive advantage as new markets develop and mature.
Recommendations for Global Health Stakeholders 
 → Context-setting institutions, such as governments and civil society, can monitor the results of shared value 
initiatives, including patient outcomes and health system improvements. Specifically, advocacy-oriented 
organizations have a role to play in ensuring that health technology companies develop strategies to expand 
access to poorer patients at the frontier of shared value in Africa and Asia. Organizations that provide 
information and insight on unmet health needs can stimulate more immediate shared value opportunities 
through patient research, value chain analysis, and health system auditing. Organizations that partner with 
companies to implement shared value strategies can be more proactive in offering their services. Lastly, 
funders can incentivize the private sector to scale-up delivery of health products to patients in remote loca-
tions or where health systems are particularly deficient.
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Shared Value in Global Health
Pharmaceutical	and	medical	device	
companies	create	shared	value	in	low-	and	
middle-income	countries	when	they	generate	
returns	for	the	business	and	address	unmet	
health	needs	at	scale.	
Introduction
Introduction
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In high-income countries, companies have contributed to enormous improvements in health and 
well-being and they have prospered as a result. Low- and middle-income countries have benefitted 
to a much lesser extent, and have often been an afterthought for the leading firms. While a strong 
moral case has long been made for health technology firms to address unmet health needs in low- 
and middle-income countries, until recently, the commercial opportunity has been much less 
apparent. 
Over the last decade, global health activists, representing the interests of the underserved, have 
been successful in pushing equitable access onto corporate agendas. Leading companies responded 
with dozens of thoughtful, philanthropic partnerships to increase access to their products. While 
these partnerships introduced companies to unmet health needs, they did little to change the prod-
ucts sold, the people selling them, and investments in health systems. The disease burden in some 
low- and middle-income countries was perceived as a market failure, and the attendant health 
product R&D and delivery barriers were seen as too high to overcome. 
In a marked change, pharmaceutical and medical 
device firms are now seizing opportunities to create 
shared value. They are beginning to realize that, in 
many cases, meeting some needs of the underserved 
in low- and middle-income countries may prove an 
important source of future growth and profitability. 
Likewise, the global health field recognizes that 
firms can have more impact when they act as busi-
nesses to solve health problems. 
The future can be seen, for example, in the commer-
cially-sustainable Arogya Parivar business of 
Novartis, which reaches 42 million underserved people — many with incomes below $5 per day — 
in 33,000 villages across 10 Indian states. To create shared value, the company tailored its portfolio 
of products and services, reinvented its approach to sales and distribution, and invested in health-
worker training and patient education. In the process, it contributed significantly to the well-being 
of patients and health systems. 
Such innovation cannot address every global health challenge. Systemic market failures exist in 
health technology, notably around neglected diseases, where needed products and services are not 
being developed or delivered on a commercial basis due to the inability of patients to pay. These 
market failures are a genuine issue that shared value cannot address, at least in the short term. 
Saving lives, and reducing suffering and ill-health, are the 
purpose for which pharmaceutical and medical device 
companies exist, and the ultimate source of their value creation. 
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Yet, recognition is growing that market failures do not explain all unmet health needs in low- and 
middle-income countries. 
Companies can reach many people — often poor but not destitute — who have limited access to 
health care today, but who could viably be reached through shared value approaches. For example, 
by 2030, 87 million individuals are projected to have diabetes in India. The private sector could 
serve a significant number of these patients.5 Moreover, the shared value frontier that marks the 
boundary between new markets and true market failure is not fixed. Today’s genuine market fail-
ures are often tomorrow’s shared value opportunities (see Figure 2 below).
Most corporations are still at an experimental stage of shared value. But early findings are 
revealing commercial, patient, and health system benefits. For example, two-thirds of BD’s (Becton, 
Dickinson and Co.) growth will come from low- and middle-income countries in 2011.6 Novo 
Nordisk has saved an estimated 140,000 life years (as of year-end 2010) since entering the Chinese 
market in the mid-1990s, through improved products for diabetes treatment, increased physician 
training, and greater patient education.7 In the process, it has achieved a 63 percent market share in 
a market worth more than $1 billion in 2010 and has grown in value at nearly 40 percent per year.8 
The challenge for the health technology sector, and for the global health field as a whole, is to 
accelerate these trends. Companies increasingly recognize the potential to create shared value, but 
they are still searching for the best ways to invest and act. Promising examples exist, particularly 
in China and India, which have developed into test beds for shared value in global health. This is 
due to the size and growth rates of their markets, as well as strong manufacturing clusters that 
can deliver the volumes needed for success. Market penetration is advancing more slowly within 
the lower-income and rural markets of India and China, while commercial investment is still at a 
nascent stage in less developed countries in Asia and Sub-Saharan Africa — although signs point to 
progress there, too. 
Introduction
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DEFINITIONS, SCOPE, AND METHODOLOGY
Definitions	and	Scope
This paper’s title and focus, “Competing by Saving Lives: 
How Pharmaceutical and Medical Device Companies 
Create Shared Value in Global Health,” encompasses 
two specific concepts.
Michael Porter and Mark Kramer defined the idea of creating 
shared value as, “enhanc[ing] the competitiveness of a 
company while simultaneously advancing the economic 
and social conditions in the communities in which it 
operates.”10 While we recognize that many health-related 
industries contribute to public health, we have chosen to 
focus on pharmaceuticals and medical devices, which we 
refer to collectively as the health technology sector. We 
have selected these industries because they are newly 
motivated to enter low- and middle-income markets, 
and their specific market entry approaches have not 
yet been documented. We acknowledge the inherent 
differences in how the two industries function, yet, the 
range of shared value opportunities in low- and middle-
income countries is similar. In particular, we concentrate 
on large, multinational corporations that have been at 
the center of dialogue in recent years and have the 
resources to act at scale (see Figure 3 for list of top 
10 pharmaceutical and medical device companies by 
revenue). Other publications document valuable lessons 
from small- and medium-scale social enterprises.11
Global health is defined as the science and practice 
of “improving health and achieving equity in health 
for all people worldwide.”12 For reasons of scope, we 
have chosen a narrower definition, with the same spirit. 
Specifically, we consider the health needs of underserved 
populations in low- and middle-income countries, 
according to the World Bank country classification 
system.13 We acknowledge that unmet health needs also 
exist in developed countries. However, we have chosen 
to focus on low- and middle-income countries because 
they account for a disproportionate amount of the global 
disease burden, their resources to address the challenge 
are much more limited, and until recently, they have 
garnered little attention from most pharmaceutical and 
medical device companies.
While we believe the concept is uncontroversial, the 
term “underserved populations” has not been explicitly 
defined in the literature.14 We therefore use the following 
working definition throughout the report: Underserved 
populations are people who, through poverty, poor 
health technology coverage, or weak health systems, 
lack access to health services that meet their needs.
This report explores how pharmaceutical and medical device companies are starting to seize 
shared value opportunities, and how, in doing so, they can be authentic partners in improving 
health outcomes for the underserved. It builds on the work of many others, such as C.K. Prahalad, 
and is indebted to existing concepts of inclusive business models in developing countries.9 Our 
analysis is informed by an extensive literature review, secondary research on health technology 
firms, and more than 70 expert interviews (see the bibliography and list of interviewees). 
The report covers new ground, offering a framework for specific firm-level actions and collabora-
tions. We illustrate how companies are creating shared value by reconceiving their products and 
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Methodology
In formulating the conclusions laid out in this paper, 
FSG conducted or developed a literature review of more 
than 90 reports, secondary research on pharmaceutical 
and medical device companies, and 70 interviews with 
industry leaders, government and funder representatives, 
and other stakeholders.
…the	global	health	field	recognizes	that	firms	can	have	more	impact	
when	they	act	as	businesses	to	solve	health	problems.
Figure 3: Top 10 Companies by Revenue per Segment (2010)
Top 10 Originator  
Pharmaceutical  
Companies
 
2010 Sales 
(Bn)
Top 10 Generic  
Pharmaceutical  
Companies*
Q1-Q2 
2010 Sales 
(Bn)**
Top 10  
Medical Device  
Companies
 
2010 Sales 
(Bn)***
Pfizer $ 55.6 Teva $ 11.0 Johnson & Johnson $ 26.5
Novartis $ 46.8 Novartis (incl. Sandoz) $ 7.2 GE Healthcare $ 16.8
Merck & Company $ 38.5 Mylan $ 6.2 Siemens $ 16.1
Sanofi-Aventis $ 35.9 Abbott (incl. Piramal) $ 3.4 Medtronic $ 15.8
AstraZeneca $ 35.5 Pfizer $ 3.2 Philips Healthcare $ 8.7
GlaxoSmithKline $ 33.7 GlaxoSmithKline $ 3.0 Covidien $ 8.5
Roche $ 32.7 Unknown Manufacturer $ 3.0 Roche $ 8.4
Johnson & Johnson $ 26.8 Merck & Company $ 2.7 Boston Scientific $ 7.8
Abbott $ 23.8 Sanofi-Aventis $ 2.8 Abbott $ 7.8
Eli Lilly and Company $ 22.1 Watson $ 2.5 BD $ 7.4
Source: IMS Health Midas, December 2010. *  Includes originator pharmaceutical 
companies with presence in the generics 
drug market through subsidiary companies, 
acquisitions, or in-licensing agreements. 
** Based on IMS sales data through Q2 2010.
Note: Other well known manufacturers,  
Cipla ($942 M) and Dr. Reddy ($1.2 Bn FY10), 
fall below the list in revenue.
Source: IMS Consulting Group report to the 
Bill & Melinda Gates Foundation, 2011.
*** Estimated device-only revenue.
Source: “The Global Medical Device Market, 
2nd Edition,” Kalorama Information, April 
2011.
markets; redefining productivity in their value chains; and strengthening their clusters — the 
ecosystems of supporting industries, competitors, health systems, governments, and civil society 
actors in which they operate. We also discuss five key principles for how companies can plan, 
implement, and manage such efforts. Ultimately, we seek to advance the discussion about the 
health technology sector’s role in global health and trigger further action among companies and 
stakeholders alike.
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Background
A	common	assumption,	that	companies	have	
little	commercial	interest	in	meeting	the	health	
needs	of	the	world’s	underserved	in	low-	and	
middle-income	countries,	is	being	disproven	
by	changing	populations,	disease	burdens,	and	
economic	conditions.	Newly-recognized	market	
opportunities	for	companies	are	emerging	
around	the	enormous	unaddressed	health	needs	
of	low-	and	middle-income	countries.
13Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
When the pharmaceutical and medical device industries 
became fully established following World War II, they 
embodied the idea of shared value. 
Companies invested in risky R&D to develop revolutionary, life-saving technologies; in return, 
society provided them with intellectual property protections that rewarded success.15 As a result, 
society gained from transformative advances in health technology, ranging from antibiotics to arti-
ficial hearts. These innovations have helped to raise life expectancy in most developed countries by 
more than a decade since 1945.16 Companies have also benefited: In 2011, the 18 health technology 
firms in the Fortune 500 generated more than $350 billion in revenues and employed more than 
700,000 people.17
Over time, this social contract has been called into question. Health technology companies have 
focused ever more narrowly on developing similar products for well-understood indications in 
safe, bankable markets. The global poor were generally an afterthought, even as the World Health 
Organization (WHO) and others moved to recognize their health needs as a human right. The 
result has been that even as lives in the developed world have been transformed, the underserved in 
low- and middle-income countries have been left behind (see Figure 4).18
EASTERN MEDITERRANEAN   6% | 1% | 1%
SOUTH-EAST ASIA 19% | 4% | 3%
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In 2008, cardiovascular disease led to more than 17 million deaths globally — the single biggest 
cause of mortality. Yet only 4 percent of these deaths occurred in high-income countries, while 
low-income countries accounted for 42 percent.19 Moreover, just 5 percent of global spending 
on cancer occurs in low- and middle-income countries, even though they account for almost 80 
percent of the cancer burden in terms of life-years lost.20 This burden is felt at least as much in 
large middle-income markets like India and China as it is in less developed countries. Recent esti-
mates suggest that more than twice as many poor people live in South Asia as in Africa.21
Nonprofit organizations, multilaterals, and foundations stepped in to try to fill the gap, in the 
absence of industry engagement. Organizations like the Treatment Action Campaign in South 
Africa, Médecins Sans Frontières (MSF), and Oxfam International progressively increased pres-
sure on pharmaceutical companies to supply essential products to low- and middle-income 
countries at reduced cost, and to increase marketing transparency. Pharmaceutical companies 
responded to this pressure with philanthropy. In the best cases, such as Merck’s Mectizan dona-
tion program and Pfizer’s Global Health Fellows program, companies leveraged corporate assets 
to address specific health issues. In many other cases, however, companies concentrated on being 
seen to do the right thing — or, at least, on not being seen doing the wrong thing — rather than on 
more concerted efforts to address the underlying problems of access, quality, and cost of health 
products. Moreover, philanthropic engagements were accompanied by controversial efforts to 
protect intellectual property rights, such as the Pharmaceutical Manufacturers Association of 
South Africa’s decision in 1998 to sue the government of South Africa over its medicines policies 
on behalf of 39 companies.
More recently, companies’ philanthropic efforts have grown in volume and sophistication, particu-
larly during the last ten years. In 2009, the value of pharmaceutical donations and corporate social 
responsibility programs directed toward developing countries was estimated to be $3.4 billion — a 
two-fold increase since 2005.22 In 2010, 102 R&D projects for the so-called “diseases of the devel-
oping world” (the ten diseases prioritized by the Programme for Research and Training in Tropical 
Disease) were underway directly by pharmaceutical companies or in partnerships with a Product 
Development Partnership.23  In 2006, 49 similar R&D projects were sponsored by pharmaceutical 
companies.24 Initiatives such as the Access to Medicine Index, the GAVI Alliance, and Advanced 
Market Commitments have begun to create a pull for companies to engage on global health issues, 
complementing the push for public health advocacy. These initiatives have been effective in begin-
ning to bridge the market failure around neglected tropical diseases and other diseases of the poor, 
and they will continue to be necessary for many years to come. 
Nevertheless, such efforts have been underpinned by a common assumption, shared by the 
industry and its stakeholders: companies have little commercial interest in meeting the health 
needs of the world’s underserved in low- and middle-income countries. At best, both sides have 
seen companies’ role as being suppliers to the global health field. Civil society and government 
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pressure over price and marketing practices can be seen as advocacy for better deal terms; the 
donations and discounts described above reflect companies’ response. 
Key trends within the health technology sector are changing the basis for this assumption. Aging 
populations, changing disease burdens, and the effects of the financial crisis have led traditional 
health systems to scrutinize costs as never before. Countries are asking hard questions about the 
incremental value of new technologies. Outcome-based reimbursement decisions are gaining 
in popularity, as reflected in the actions of such agencies as the National Institute for Health 
and Clinical Excellence in the U.K. and the Institute for Quality and Efficiency in Health Care 
in Germany. At the same time, R&D productivity has fallen, particularly for pharmaceutical 
firms. The proportion of total 2009 sales from drugs launched in the prior five years was below 7 
percent.25 Average investment per new and approved drug has quadrupled between 2000 and 2009, 
reaching around $4 billion.26
In parallel, newly recognized market opportunities are emerging around the enormous unad-
dressed health needs of low- and middle-income countries. Many Asian and African countries, in 
particular, face a double burden of infectious disease and increasing rates of non-communicable 
diseases (NCDs), such as cardiovascular disease, diabetes, and cancer. NCDs in low- and middle-
income countries caused half of all deaths worldwide — around 34 million — while 96 percent of all 
deaths due to infectious diseases also occurred in those nations.27 Meeting the needs of these coun-
tries represents one of the biggest opportunities for the health technology sector in the coming 
years.28
For example, the medical device markets in India, China, and Vietnam are each growing at more 
than 10 percent per year, and are forecast to be worth more than $20 billion by 2015.29 Brazil, 
Russia, India, and China are expected to more than double their pharmaceutical spending, rising 
from $90 billion in 2010 to $194 billion in 2015.30 IMS forecasts that spending on medicines will 
grow at 13 percent to 16 percent per year from 2010 to 2015 in 17 high-growth markets, including 
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China, India, Brazil, Indonesia, Vietnam, South Africa, and Pakistan.31 By comparison, global 
spending on medicines is forecast to grow at 3 to 6 percent annually through 2015, slowing from 
6.2 percent per year over the previous five-year period.32 Overall, analysts forecast that low- and 
middle-income countries will account for 75 percent of all growth in the pharmaceutical sector 
from 2011 to 2020.33
Companies can respond to these disease challenges and market opportunities in a number of ways. 
For those that can build a competitive advantage in niche, personalized technologies, a continued 
focus on developed countries may make strategic sense. In most cases, though, corporate strategies 
in the medical device and pharmaceutical industries will increasingly focus on low- and middle-
income countries. 
To compete in these markets, companies can continue to act as suppliers, and simply wait for 
economic growth and strengthened health systems to make their value proposition relevant 
beyond a small, wealthy elite. Alternatively, they can seize the initiative to reach underserved 
segments today and grow their businesses. Doing so is not without risk. The rules of competition 
vary greatly, lack of information makes it difficult to identify and characterize opportunities, and 
political instability and weak infrastructure hamper execution. 
Nevertheless, as shown in this report, companies are confronting these barriers with new 
approaches. While it is still early, the potential gains — both for society and for companies — are 
substantial.
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SETTING THE CONTEXT: EVOLVING ATTITUDES TO SHARED VALUE AMONG 
CIVIL SOCIETY AND SHAREHOLDERS 
The health technology sector has been subject to significant 
attention from both civil society and the investment 
community over the last twenty years. Nonprofit, advocacy 
organizations have had a long-running dialogue with 
the sector, often sharply criticizing the lack of effective 
engagement to meet the needs of the underserved. 
Shareholders have valued the consistent, high returns 
that many firms have been able to generate, but have 
shown little interest in long-term opportunities in low- 
and middle-income countries. These attitudes have set 
the context for corporate decision-making around levels 
of investment and quality of engagement in meeting 
global health needs. As shared value opportunities for 
health technology companies have become more evident, 
attitudes are changing, albeit with some important caveats. 
Civil	Society	
Pharmaceutical firms have had a mixed relationship 
with civil society — far more tense than medical device 
firms. For the pharmaceutical industry, engagement on 
global health issues is interpreted through the historical 
lens of HIV/AIDS. HIV/AIDS activists played a key role in 
demanding change from the industry, and pharmaceutical 
companies’ reticence to support expanded access led to 
a reputational crisis. In more recent years of the epidemic, 
the industry responded with many partnerships to 
support the treatment of HIV/AIDS and other infectious 
diseases. This legacy of battles over HIV/AIDS makes some 
pharmaceutical companies overly cautious regarding 
involvement in global health issues, particularly where 
the underserved in low- and middle-income countries 
and potential profits are involved.
Many issues still remain contentious. Organizations 
like Oxfam International and Médecins Sans Frontières 
highlight a lack of R&D for neglected diseases and observe 
that many life-saving medications remain financially out 
of reach for the poorest people. The greatest ongoing 
criticism focuses on intellectual property. In particular, 
critics cite the pharmaceutical industry’s defense of 
its patents and its challenges to governments that use 
emergency mechanisms made available through TRIPS 
(Trade-Related aspects of Intellectual Property Rights). 
Such mechanisms force companies to offer licenses to 
produce their medicines.
As demonstrated in this report, the health technology 
sector has shared interests in strong health systems, 
disease awareness among patients and providers, 
efficient distribution, and fair rules around competition. 
As companies move toward more sustainable, strategic 
solutions to improve access to medicines in low- and 
middle-income countries, old mindsets may change. 
To understand the changing perspectives about pharmaceutical 
and medical device firms, FSG partnered with the Global 
Health Council (GHC) to conduct an online survey of its 
members, which it administered in August 2011. These 
global health actors see pharmaceutical and medical 
device companies as important partners in meeting global 
health needs. An overwhelming majority of respondents 
(79 percent) believe that companies in these industries 
are important contributors to their mission, and are open 
to engaging with companies (see Figure 6).
Respondents see these industries as making global health 
issues a priority, because of their business relevance, not 
just their image-enhancing benefits. Sixty-two percent 
of respondents believe that the industries view global 
health issues as relevant from a commercial perspective, 
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while 32 percent believe that they view global health 
issues from a reputational perspective. 
Respondents indicated that a company’s actions related 
to product safety and access had the most impact on 
their reputation. In contrast, philanthropic contributions 
and employee engagement activities — and surprisingly, 
even new products — did not have as strong an influence. 
Shareholders
Currently, the investment community (with the exception 
of socially responsible investment analysts such as 
Henderson, Aviva, and others) pays minimal attention to 
health technology firms’ engagement in global health. The 
first mainstream analyst report to touch on the subject, 
published by UBS, appeared in 2010.34 For the most part, 
shareholders and analysts are adopting a wait-and-see 
approach to how companies address low- and middle-
income markets.
As companies move toward shared value in global health, 
and their efforts begin to contribute significantly to financial 
results, this is likely to change. Indeed, UBS pharmaceutical 
analyst Gbola Amusa believes that penetration into 
emerging markets will start to be a driver of European 
companies’ share prices as early as 2012, as the effects 
of patent expirations work their way through the system 
(though it may take longer for American firms).
Early movers in the investment community, such as the 
Pharmaceutical Share Owners Group, have already begun 
to recognize the opportunity that unmet health needs 
represent. The coalition of socially-minded investors had 
an important influence on getting access to medicines 
issues onto the boardroom agendas of pharmaceutical 
companies. The PharmaFutures series of investor dialogues 
has paid increasing attention to this question, focusing 
on emerging markets in its third publication in 2008 and 
on shared value in its fourth publication in 2010. In May 
2011, 29 institutional investors, who together manage 
$3.7 trillion in assets, signed a statement, developed 
with the Access to Medicine Foundation, stating that 
they considered pharmaceutical companies’ efforts to 
reach the underserved “potentially material to long-term 
shareholder value creation.”35
How do pharmaceutical and medical device 
companies fit with your organization’s mission?
(N=126) 
Overlapping Goals with the Industry 
but We Would Rather Not Partner
Barrier to Us Fulfilling Our Mission
Do Not Affect Our Ability to Fulfill Our Mission
Overlapping Goals with the Industry 
and We are Open to Partnerships
Essential Partners for Us to Fulfill Our Mission
Figure 6: 
Importance of Companies 
to Respondents’ Mission
40%
39%
5%
14%
2%
Source: FSG-Global Health Council Survey, 2011
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Shared Value Opportunities  
in Global Health
Two factors are necessary to create shared 
value. First, companies need to reorient 
themselves to systematically and relentlessly 
uncover new, unmet needs, and find new 
and better ways to address them. Second, 
to achieve meaningful impact and attractive 
economic returns, firms need to do so at 
scale.
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Companies create shared value in global health when they 
compete on the basis of improving health outcomes for the 
underserved. 
Rather than competing for market share among well-funded payers and wealthy patients, compa-
nies view their success in terms of their ability to improve health outcomes by building and serving 
new markets. To achieve that success, companies must think differently about how they run their 
businesses.
Two factors are necessary to create shared value. First, companies need to reorient themselves to 
systematically and relentlessly uncover new, unmet needs, and find new and better ways to address 
them. Second, to achieve meaningful impact and attractive economic returns, firms need to do so at 
scale.36
Low- and middle-income countries have vast unmet needs. In 2010, 34 million people were living 
with HIV/AIDS, two-thirds of whom were in Sub-Saharan Africa.37 Low- and middle-income 
countries account for nearly 80 percent of the burden from such NCDs as cardiovascular disease, 
diabetes, cancer, and chronic respiratory diseases, which together caused 63 percent of all deaths 
in 2008.38 Estimates put the number of people in 
Asia, Africa, and Latin America suffering from 
asthma in 2004 at more than 130 million, with 
particularly high rates reported in Peru, Brazil, and 
South Africa.39 More than 55 percent of the nearly 
13 million cancer cases recorded in 2008 were in 
low- and middle-income countries; by 2030, those 
countries are expected to account for two-thirds of 
an estimated 21 million cases.40, 41 Seventy percent 
of the estimated 285 million people with diabetes 
in 2010 lived in these nations, and diabetes rates 
are expected to nearly double by 2030, with low- 
and middle-income countries seeing the largest 
increases.42 In India and China, diabetes, heart 
disease, and stroke are expected to cost more than 
$750 billion from 2005 to 2015.43 Overall, estimates 
suggest that NCDs could cost more than $30 trillion 
over the next 20 years and could lead to a global loss 
of output of $47 trillion.44
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Source: Causes of Death 2008, World Health Organization
Figure 7: 
Top Five Non-Injury Causes of Death 
in 2008
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Addressing unmet health needs in these markets will not be easy, even for companies that excel 
at innovation, market adaptability, and stakeholder management. While most of the conversation 
about the private sector’s role in global health has centered on gaps in upstream R&D activities, 
many of the problems to overcome are downstream, delivery-based challenges. Five key barriers to 
scaling business in low- and middle-income countries are identified in the literature: missing skills 
and knowledge, limited market information, ineffective regulation, inadequate infrastructure, and 
limited access to financial products and services.45 In addition to these factors, health technology 
firms are challenged to adapt their often complex products for countries with limited resources 
or patient ability to pay. Local health systems also may not be capable of delivering their products 
safely and effectively.
Companies are addressing these barriers through specific approaches across three levels of shared 
value that have an increasingly external emphasis. First, companies can reconceive their prod-
ucts and markets, devising new ways of addressing unmet health needs and developing more 
affordable and appropriate products. Second, they can redefine productivity in the value chain, 
to reach underserved groups affordably and at scale. Third, they can enable local cluster develop-
ment, strengthening the systems, infrastructure, and context that allow products to be delivered 
competitively and sold widely.
Corporate efforts to reconceive products and markets are perhaps the most advanced across the 
three levels of shared value (see Table 1). Many firms have adopted tiered or discounted pricing 
for poor consumers.46 In addition, companies are redeveloping existing product lines to meet the 
needs of these new markets, either by lowering unit costs or improving functionality in resource-
poor environments. The most compelling initiatives are the result of companies thinking more 
broadly about the needs and behaviors of specific segments of the population, and developing ways 
to address them affordably and at scale. In general, successful approaches are patient-centered, 
affordable, and tailored to local conditions.
Figure 8: Levels of Shared Value Creation for the Health Technology Sector
1 Reconceiving Products  and Markets 2 Redefining Productivity  in the Value Chain 3 Enabling Local Cluster  Development
• R&D for drugs, vaccines, and 
devices that fill unmet health 
needs
• Adaptation of existing 
products to reduce complexity 
and cost
• Tailored product offerings to 
meet local market conditions
• Collaborative and homegrown 
R&D to reduce cost and risk
• Efficient, local supply chains 
and manufacturing to reduce 
production costs
• Locally-adapted sales and 
distribution to penetrate new 
markets and better meet 
patient needs
• Behavior-change campaigns to 
increase the sophistication of 
demand for health care
• Health system strengthening 
to enable delivery of needed 
products and services
• Advocacy and capacity build-
ing to strengthen policy and 
the regulatory environment
22
Shared Value Opportunities in Global Health
Table 1: Reconceiving Products and Markets
Area of Activity Approaches Examples
R&D for drugs, vaccines, 
and devices that fill 
unmet health needs
• New technologies for 
diagnosis, prevention, 
or treatment
• New delivery 
mechanisms
• Daiichi Sankyo, through its generics subsidiary, Ranbaxy 
Labs, partnered with the Indian government to develop new 
tuberculosis drugs
• Boehringer-Ingelheim developed extended-release, once daily 
Viramune® (nevirapine) for HIV treatment that aims to replace 
twice daily, immediate-release tablets of nevirapine, reducing 
the pill burden
Adaptation of existing 
products to reduce 
complexity and cost
• Re-engineering / 
reformulation to 
improve functionality
• Redesign to lower unit 
cost 
• Dr. Reddy invested in a cardiovascular disease polypill, the 
“Red Heart Pill” which combines several products and could be 
widely distributed to lower the risk of the disease
• GE, through its healthymagination platform, developed an ECG 
machine suitable for mobile use in difficult environments (see 
company profile)
• Medtronic developed a leadless pacemaker that can be 
monitored remotely, where seeing a specialist regularly can be 
difficult (see company profile)
• Abbott’s True Care business in India launched a combination 
of two antibiotics specifically developed to address the issue 
of drug-resistant typhoid
Tailored product 
offerings to meet local 
market conditions
• Product portfolio 
selection
• Tiered pricing
• Adapted packaging 
to reduce unit cost or 
improve safety
• Novartis selected a portfolio of patented, generic, over-the-
counter and consumer products for its Arogya Parivar business 
in rural India (see company profile)
• GSK set prices for its patented products in the least developed 
countries at a maximum of 25 percent of the price in the U.K. 
or France
• Merck KGaA, Johnson & Johnson and GSK are working with 
technology company Sproxil to roll out a mobile phone-based 
drug authentication system in Nigeria, Kenya and India; May & 
Baker Nigeria is working with HP and mPedigree on a similar 
system
• GSK repackaged its Ventolin® asthma medication from a 
200-dose pre-filled inhaler at $5 each to packs of two to three 
doses retailing for just a few cents 
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GE’s healthymagination initiative was founded 
as a platform to coordinate research and 
development across the company, with the aim 
of launching products that would lower-cost, 
enhance quality, and expand access. The company 
set ambitious targets of investing $3 billion 
to develop more than 100 healthymagination 
products that would improve on cost, quality, 
and access targets by 15 percent each by 2015. 
Establishing healthymagination in May 2009 was 
an essential step in setting the broad corporate 
focus on in-country, for-country innovation. 
The company recognized that, given the highly 
localized nature of health needs, it needed to 
give local teams the independence to innovate 
inside a market, for that market. The company’s 
view was that reverse innovation demanded a 
decentralized, local-market focus — one that 
fundamentally conflicts with the centralized, 
product-focused structure that for years had 
been the standard way to compete globally. 
Local teams in China, India, and other emerging 
markets were given unprecedented autonomy 
to innovate for their markets. By taking an 
experiment-and-learn approach, the teams 
spent a little and learned a lot.
GE saw a need to grow its business in India, as 
the country represented only 2 percent of GE 
Healthcare’s revenue in 2010. GE also noted 
the rapid growth in cardiovascular disease 
in the country, including the 70 percent of 
people living in rural areas, who may not have 
consistent access to electricity. The company 
developed its MAC line of electrocardiogram 
(ECG) machines, a more portable and affordable 
version of the common cardiac diagnostic 
device to extend access to rural areas. The 
machines have simplified operations, run on a 
highly efficient battery, and sell for as low as 
$500, compared with GE Healthcare’s hospital-
based units, which can cost tens of thousands 
of dollars more. GE has sold 10,000 of the units 
to date, with individual physicians purchasing 
90 percent of the ECGs so far. GE leaders cite 
the importance of proximity to local markets in 
facilitating the adaptations needed to innovate 
in emerging markets.
GE: 
Adapting Existing 
Products to Reduce 
Complexity and 
Cost47 
COMPANY PROFILE
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As companies learn how to deliver reconceived products to new markets, investments to boost 
value chain productivity will become more common (see Table 2). Innovative partnerships 
are emerging to share the risks and reduce the costs of R&D, such as ViiV Healthcare. Firms are 
experimenting with a range of new approaches to improve the efficiency and reliability of their 
manufacturing and sourcing. Gilead, for example, has entered into licensing contracts with 12 
Indian active pharmaceutical ingredient manufacturers, which has reduced its supply costs by 67 
percent.48 Companies like Abbott, Novartis, and Stryker are also developing increasingly effective 
and differentiated approaches to sales and distribution.
The potential for shared value is by no means limited to health outcomes. Companies interviewed 
for this paper noted positive effects on local job creation in particular.49 From a health perspec-
tive, though, the main opportunity for shared value lies in aligning the value chain to deliver on 
the promise of well-adapted, affordable products and services. Successful investments in this area 
improve reliability, reduce costs, and leverage local expertise. 
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Table 2: Redefining Productivity in the Value Chain
Area of Activity Approaches Examples
Collaborative and 
homegrown R&D to 
reduce cost and risk
• Investment in new or 
existing local research 
institutions
• Collaborative 
approaches to reduce 
cost and share 
development risk
• Stryker hired and trained indigenous R&D talent to develop 
India-specific products (see company profile)
• Novo Nordisk established an R&D center in China, allowing 
it to tap into the knowledge of Chinese scientists to develop 
locally-appropriate insulin products
• Hilleman Labs, a joint venture between Merck and Wellcome 
Trust, was created to develop and bring to market affordable 
vaccines for low- and middle-income countries 
• Pfizer and GSK created a new, jointly-owned company, ViiV 
Healthcare, that combines compounds owned by both firms to 
create a viable pipeline for new HIV medicines
Efficient, local 
supply chains and 
manufacturing to reduce 
production costs
• Supply chain 
strengthening
• Licensing 
• Local production 
facilities
• Improved 
manufacturing 
practices
• Gilead licensed production of active pharmaceutical ingre-
dients for HIV medication to 12 Indian companies, reducing 
supply risk and creating price competition to drive down costs 
(see below)
• Cipla has established manufacturing plants in Uganda and 
Sierra Leone in order to better serve markets in Sub-Saharan 
Africa
• The Clinton Health Access Initiative improved Aspen Pharma-
care and other generic companies’ manufacturing processes, 
established local suppliers of critical reagents, and facilitated 
new API (active pharmaceutical ingredient) supplier entry 
to reduce the price of efavirenz (an HIV medication) by 69 
percent
Locally-adapted sales 
and distribution to 
penetrate new markets 
and better meet patient 
needs 
• Sales force 
reconfiguration
• New distribution 
approaches
• Abbott has adapted its sales force to reach low-income  
populations in remote areas of India (see company profile)
• GSK is working with its distributors to share the risk of switch-
ing to a higher volume model to ensure that price reductions 
are passed on to patients
• Pfizer’s initiative, Comunidad más saludable (“Healthier Com-
munity”), in Venezuela trains community sales representa-
tives to target health clinics in low-income neighborhoods 
to promote Pfizer products, along with discount coupons for 
patients to increase access
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When Abbott bought the branded generic 
drugs business of Piramal, a major Indian 
producer, it had high expectations. The company 
anticipated establishing a leading position 
in the growing, branded generics market in 
India, which represented $8 billion in sales in 
2011 and is expected to more than double by 
2015. Abbott projects more than $2.5 billion in 
annual pharmaceutical sales in India by 2020. 
To reach these goals, the company needed new 
approaches to penetrate India’s small towns 
and rural areas, which represent 42% of the 
pharmaceutical market. A key component in 
the Piramal domestic formulations purchase 
was the True Care business unit, which brings 
high-quality and affordable medicines to 
people in remote areas of urban and rural India 
— currently some 10,000 towns and villages. 
The unit takes an innovative approach to developing 
a sales force: It hires sales representatives who 
are graduates from non-scientific disciplines, 
have local language skills, and ties to the 
communities they will target. The company 
provides intensive training, performance 
incentives, and coaching in areas like sales 
and science. 
Local sales representatives are more effective in 
selling and promoting health in their communities. 
The sales force conducts a large number of 
education programs on basic diseases for 
health care practitioners. More than 38,000 
health care practitioners took part in such 
programs in the past year. 
True Care has achieved impressive results. In the 
last four years, 58 million patients have been 
reached.  However, hurdles remain. The business 
continues to adapt the product portfolio to 
address the local disease burden and to find an 
appropriate balance between profitability and 
access. In particular, it has been challenging 
to adapt True Care to Abbott’s operational 
standards, while competing within the local 
context.  Abbott recognizes that driving both 
growth and access in these markets is a long-
term effort that will require new approaches 
to meet these challenges in the years ahead.”
Abbott:
Adapting the Sales 
Force to Penetrate 
India’s Remote 
Areas50
COMPANY PROFILE
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A leader in orthopedic care, Stryker set its 
sights on gaining market share in India five years 
ago, with an ambition to develop appropriate 
devices and orthopedic implants locally. The 
market potential was huge — approximately 
80,000 highly arthritic patients forego knee-
replacement surgery each year.
The company started with an investment in 
building indigenous R&D talent. It commonly 
recruits from such fields as automotive engineering, 
because existing skills are lacking. The company 
has provided experiential learning opportunities 
to its trainees and taught them to seek out 
health needs. Through a partnership with 
Stanford’s Biodesign group, the Sanjay Gandhi 
Postgraduate Institute of Medical Sciences, 
and the All India Institute of Medical Sciences 
(AIIMS), Stryker’s investment in training at its 
new Global Technology Center has already 
paid off. One knee system, with proven clinical 
history, has already been developed and 
launched at an affordable price for the local 
market. Stryker hopes that other India-specific 
product and business-model innovations will 
result in more appropriate local solutions. 
Currently, the country imports up to 80 percent 
of medical devices.
Stryker’s investments in R&D and new relationships 
have unlocked a key insight — trained surgeons 
are woefully inadequate and training for knee-
joint surgery is nonexistent in the country. 
Through hands-on training, demonstrations, 
and a train-the-trainer model, more than 100 
surgeons have been trained during the last two 
years. Now the company is tackling the greatest 
challenge — health care infrastructure. Stryker 
is planning to help smaller hospitals throughout 
the country build high-quality operating rooms 
with state-of-the-art technology, such as video 
linkages among operating rooms and with 
other hospitals so that surgeons can review 
their work with peers and continue to learn. 
Stryker:
Homegrown R&D  
for Orthopedic 
Care in India51 
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Perhaps most interesting from a global health perspective is the growing trend of companies 
investing in the clusters in which they operate. When pharmaceutical and medical device compa-
nies invest in health care clusters within low- and middle-income countries — to improve patient 
awareness and demand, health systems, and the policy and regulatory environment — they not 
only bolster their own ability to reach new markets, but they also provide value to society that goes 
beyond the immediate benefit of their medicines or devices to patients. 
However, many cluster efforts remain subscale, disjointed, and reactive, addressing acute prob-
lems when they arise but stopping short of creating fundamental change. Innovations that could 
alter the economics of health care provision, such as staged payment schemes and insurance, for 
example, remain rare. Nonetheless, existing investments in health care systems are likely to grow 
over time as companies build a presence in the market and begin to understand what works. In 
general, successful cluster-building efforts enable the effective and safe delivery of products 
and services to new populations; improve patient and health system ability to pay; and 
promote health-seeking behavior, by overcoming barriers such as lack of knowledge, poverty, or 
geographic distance to a health care provider.
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Table 3: Enabling Local Cluster Development
Area of Activity Approaches Examples
Behavior-change 
campaigns to increase 
the sophistication of 
demand for health care
• Social marketing 
to increase health-
seeking behaviour by 
patients
• Patient education 
about disease 
management
• Eli Lilly’s partnership with Population Services International in 
India will create new awareness about diabetes in two Indian 
cities (see company profile) 
• Medtronic’s Beijing Patient Care Center educates patients, 
physicians, and caregivers about cardiovascular therapies to 
address the lack of time that physicians have with chronic 
disease patients
Health system 
strengthening to enable 
delivery of needed 
products and services
• Improvements to 
infrastructure and 
to the capacity of 
management and staff 
• Financing innovations 
in insurance and payer 
coverage
• AstraZeneca invested in provider training and awareness to in-
crease breast-cancer treatment in Kenya (see company profile)
• Through its Amplicare program, Roche is training health pro-
fessionals on the use of innovative new diagnostics
• Sanofi-Aventis is working with the microfinance organization, 
PlaNet Finance, to develop microloans that support antima-
larial purchases in Madagascar
Advocacy and capacity 
building to strengthen 
policy and the 
regulatory environment
• National guideline 
development
• Regulatory capacity 
and efficiency
• Novo Nordisk and the World Diabetes Foundation worked 
with the Chinese Ministry of Health to improve case manage-
ment guidelines for diabetes (see company profile)
• Abbott worked to build the capacity of Chinese regulatory 
authorities to assess and approve the contents of nutritional 
products
While companies often start with one shared value approach — reduced prices for example — 
they frequently discover barriers and opportunities that demand complementary shared value 
investment. 
Gilead Sciences provides an example of how a company that starts with one activity, in this case 
licensed manufacturing, can uncover a need for complementary investments in other shared value 
approaches. As the company behind several antiretroviral drugs containing the chemical tenofovir, 
Gilead broke new ground with its licensing approach that allowed for large-scale manufacturing 
of tenofovir-based products by Indian generic manufacturers. Through voluntary licenses to 12 
generic companies operating in India, the price of these products in low-income countries has 
dropped dramatically, and 1.8 million patients living with HIV now use tenofovir-based products. 
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Of the nearly half-million deaths from breast 
cancer in 2008, 64 percent occurred in low- 
and middle-income countries.53 Breast cancer 
is a complex disease to treat, as it requires 
individual specialist attention and regular visits 
to a hospital or other health facility. Delivering 
breast-cancer care and treatment in resource-
constrained settings is especially challenging 
as these locations lack disease surveillance, 
awareness of the disease, and specialists. The 
cost of treatment can also be out of reach for 
most patients.
Against this backdrop, AstraZeneca recently 
launched Pambazuka (“Sunrise”) to expand 
access to breast-cancer treatment in Kenya, 
where fewer than 20 percent of potential 
patients are ever treated. Through careful 
analysis of the country’s referral system, the 
company identified the root causes of this low 
treatment rate: lack of awareness of symptoms 
and treatment options among patients and health 
workers, poor access to quality diagnosis, and 
a relatively high cost of treatment. Pambazuka 
aims to address these barriers by providing 
one-day breast-cancer management workshops 
for surgeons, doctors, and nurses in Kenya’s 
three largest cities. Working with the Africa 
Cancer Foundation, the program also aims 
to strengthen patient support and awareness 
by providing one-day trainings for volunteers 
and counselors who are involved in patient 
care. In addition, AstraZeneca has significantly 
reduced the price of its breast-cancer products 
— lowering the price of Arimidex 59 percent 
and Nolvadex 32 percent — in order to make 
them more affordable.
Though the program is still at an early stage 
and measurable results are not yet available, 
it still aims to be profitable as it is based on 
a similar initiative that AstraZeneca launched 
last year in South Africa. AstraZeneca seeks to 
learn from its experience with Pambazuka to 
develop similar programs in other developing 
countries where the increasing cancer burden 
is posing a significant challenge to health care 
systems that typically have not been set up 
to provide treatment for chronic conditions.
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The initiative is now profitable as the company collects a small royalty from the sale of generic 
copies of its products. 
Gilead also retains the ability to sell its branded products. To increase uptake and support for its 
11 distributors operating in 132 countries, Gilead identified the need for local cluster development 
through patient and provider educational materials, treatment guidelines, and inventory manage-
ment tools. The company is providing the necessary information to local ministries of health and 
piloting an SMS-based mHealth platform called HIV Link that allows rural community health care 
workers to communicate with HIV experts via mobile phone. 
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Efforts to create shared value across the three levels are also mutually reinforcing (see Figure 9). 
Productive and lower-cost value chains are essential to connecting redesigned product portfolios 
to underserved markets. Strong clusters can enable firms to serve population segments that were 
previously out of reach, and can open up new, lower-cost manufacturing and distribution options.
Leading firms are beginning to design multi-level approaches to harness this multiplier effect. 
Medtronic, for example, is investing in redesigned devices for use in resource-poor settings, diag-
nostic capabilities to ensure they are used appropriately, and advocacy to increase global attention 
to the non-communicable diseases. Stryker also started with product R&D but is now investing in 
its cluster through surgeon training and equipping small hospitals with improved operating rooms 
in India. GSK, Novartis, and Novo Nordisk each employ a combination of approaches across all 
three levels of shared value. 
The right combination of shared value approaches will be unique to a particular company and 
market. Factors such as disease burden, payer dynamics, regulations, health system strength, 
and cultural attitudes to health care vary both between and within countries. For a company like 
GSK, with a competitive advantage in vaccines, working through the GAVI Alliance to reach the 
underserved populations in the 48 least developed countries makes strategic sense. For others, 
such as Roche, whose strength lies more in complex-to-administer oncology drugs, middle-income 
segments in more developed countries (that are nonetheless underserved) are a more relevant 
starting point. 
Identifying the specific populations that companies are best placed to serve can be challenging. 
Market data and analytics are incomplete and hard to find.56 The definition and classification of 
unmet needs varies from country to country.57 Nevertheless, companies must apply their expertise 
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Medtronic’s business model traditionally focused 
on the development and marketing of medical 
devices in North America and Europe.55 In recent 
years, the company shifted to a strategy that 
prioritizes expansion in low- and middle-income 
countries. The company launched the Medtronic 
Global NCD Initiative with a target of reaching 
25 million patients per year by 2020. Most of 
this growth will be in treating NCDs and their 
complications. Achieving its goal will require 
investments in all three approaches to shared 
value, and a major shift in the company culture. 
The company’s product offerings must be 
reengineered to fit lower-tech health systems. 
For example, seeing a specialist regularly is 
difficult in many poorer countries. Innovations 
like a leadless pacemaker that can be monitored 
or controlled remotely therefore have significant 
potential to enhance the quality of care, and 
could also be implanted with less invasive 
procedures. Other product reengineering 
opportunities being explored include lower-
cost disposable insulin pumps, and new drug 
delivery approaches for Alzheimer’s disease. 
Medtronic also sees a need to improve the 
clusters associated with upstream diagnosis 
and care. Executives at Medtronic’s cardiac 
business in India realized that the primary access 
challenge was related to diagnosing the need 
for a pacemaker, not in the device itself. The 
company partners with organizations attempting 
to bridge this gap, such as Maestros, a provider 
of telemedicine-based EKG interpretation 
services that will improve access to cardiac 
screening.
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in segmentation and innovation to these new markets to uncover the most promising opportunities 
and design effective strategies to seize them.58 
As companies penetrate more deeply into lower income and rural markets in India, China, Brazil, 
and South Africa, or in least developed countries such as Kenya, more barriers are confronted. 
To address these barriers and move further into the shared value frontier, companies will further 
innovate and adopt more comprehensive strategies that utilize approaches within all three levels 
of shared value creation. 
Some companies are expanding the shared value frontier. In rural India, for example, Novartis aims 
to expand the reach of Arogya Parivar to 100 million people. GSK India employs more than 100 
staff dedicated to expanding its penetration into rural areas, and is investing in strengthening the 
health infrastructure in six states to support this process. Similarly, Sanofi-Aventis and GSK are 
already starting to explicitly add least developed countries to their business focus. Building on its 
success in China, Novo Nordisk is considering taking a focused approach to diabetes in a range of 
developing countries including Bangladesh and Nigeria. 
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GENERICS COMPANIES: AFFORDABLE PRODUCTS, EFFICIENT VALUE CHAINS, 
BUT LIMITS TO SHARED VALUE59 
Generic pharmaceutical manufacturers are better placed 
than their traditional, R&D-led counterparts to create 
shared value in global health in several ways. Due to 
efficient, local supply chains and manufacturing, they can 
keep operating costs low and local production volumes 
high, which often allows them to price more competitively 
than R&D-led firms. It may also be easier for them to 
compose a broad product portfolio, since many are able 
to source or manufacture a wide range of compounds, 
while traditional pharmaceutical companies may be 
optimized for those chemical entities and therapeutic 
areas for which they hold patents. As a result, generics 
companies often enjoy a competitive advantage in 
developing tailored product offerings that align with local 
market conditions in low- and middle-income countries.
However, generics companies’ ability to beat traditional 
firms on price also makes them significantly less well-
placed to work in other ways. Most lack the capability or 
investment capital to conduct R&D for new technologies 
that fill unmet health needs. Moreover, smaller generics 
manufacturers have little footprint outside their home 
markets, and may therefore struggle to develop competitive, 
locally-adapted sales and distribution channels. Of 
12 low- and middle-income country-based generics 
companies analyzed by IMS in 2011, 9 generated more 
than half their revenues from their domestic markets.60 
Also, their relatively thin margins mean they may have 
limited capacity to invest in strengthening the cluster in 
order to expand their markets and reach new patients.
These differences are beginning to blur as the structure 
of the industry changes. Leading generics companies are 
moving into territory in which traditional pharmaceutical 
companies have enjoyed an advantage. Leading generics 
firms have begun to invest in product development 
capabilities, initially focused on adaptation of existing 
products to reduce complexity and cost. Dr. Reddy, for 
example, leveraged its ability to manufacture a broad 
range of chemicals to formulate its single-dose Red 
Heart Pill, which is easier to administer correctly. Cipla 
is moving into unpatented biopharmaceuticals through 
the production of “bio-similars” with even the possibility 
of “bio-betters”, drugs better than the originators, in 
addition to development of CFC-free inhalers, a new 
delivery mechanism.61,62
Additionally, the industries themselves are converging. 
Two different types of generics companies can already 
be discerned: commodity manufacturers that continue 
to compete exclusively on price, and larger “branded 
generics” firms that seek to build trusted brands for which 
they can charge a premium. Many generics companies 
have entered supply alliances with originals manufacturers 
to provide active pharmaceutical ingredients or to 
manufacture patented medicines locally under license. 
Finally, there has been a wave of recent mergers, such 
as Daiichi Sankyo’s purchase of Ranbaxy or Sanofi-
Aventis’ acquisition of Zentiva. Indeed, 6 of the top 
10 generics manufacturers are also leading traditional 
R&D-led firms, with a collective global market share of 
20 percent by value.63 
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In 2007, Novartis launched a new initiative 
called Arogya Parivar (AP), which focuses 
on rural Indians earning between $1 and $5 
per day. It has set a goal of developing a 
sustainable, scalable business to reach this 
underserved group. In designing the business, 
Novartis carefully analyzed the local disease 
burden, and developed a tailored portfolio of 
affordable medicines, drawing from its originals, 
generics, and over-the-counter businesses. It 
recruited local sales teams to work in areas 
where workers knew the culture and spoke 
the dialect, providing access to crucial market 
intelligence and reducing mistrust among potential 
customers. In parallel, Novartis invested in an 
arm’s-length program for community health 
education, in order to tackle the chronic lack 
of health-seeking behavior that it had identified 
as a key barrier.
Rural India is a massively underserved health 
market. While approximately 70 percent of the 
Indian population lives outside urban areas, they 
account for just 22 percent of health spending 
and many do not seek formal health care at all. 
Among those who do seek health care, people 
commonly wait to visit a clinic or hospital until 
a condition becomes acute, rather than seeking 
treatment more quickly. More than two-thirds 
of health spending is out-of-pocket. 
Not all of the challenges were well understood 
at the beginning. In particular, the company 
initially underestimated the extent to which 
infrastructure issues would impede growth. 
The unreliability of the supply chain reduced 
patients’ trust in the system and willingness to 
return for care, so Novartis invested in developing 
a dense network of local distributors, in order 
to reduce stock-outs. Through the Credit for 
Health Initiative, it is also working with local 
microfinance partners to counter a lack of 
finance that was limiting the development 
of new clinics and health providers. Finally, 
to bridge the infrastructure gap in the short 
term, AP organizes frequent health camps to 
bring physicians into rural areas. In addition to 
expanding health care access, these camps can 
provide an additional sales channel for AP’s 
portfolio of products (the choice of medicine 
is at the doctors’ discretion and not limited to 
Novartis products), as well as a small source 
of income for the doctors who participate.
Four years since its inception, the initiative is 
beginning to see real results. It broke even in its 
31st month of operation and is now generating 
profits. Nascent evidence is emerging about 
improved health outcomes, although the 
company acknowledges that more work is 
required for effective measurement. To date, 
the initiative covers 42 million people in 33,000 
villages across 10 Indian states. After the health 
camps arrived, doctor visits in these villages 
tripled, from 9 percent to 23 percent of local 
populations.
Novartis has ambitious plans to scale and 
replicate AP, and has created the Social Business 
Group to oversee the process. Within India, 
the company has set a goal of reaching 100 
million people in 100,000 villages across all 
23 Indian states over the coming years. It is 
also seeking to replicate the model in other 
Asian and African countries, starting with 
Kenya and Vietnam. The firm recognizes that 
only some of what has been learned in India is 
applicable elsewhere, and that its efforts must 
be tailored to each new location. While low 
levels of health-seeking behavior are expected 
to be a common challenge, the method of 
addressing this problem will differ according 
to local needs, regulatory environments, and 
cultures. Similarly, the product portfolio will 
need to be aligned with local disease burdens 
and market structures, and in Kenya’s case, 
with a lower ability to pay.
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Novo Nordisk was one of the first Western firms 
to enter the Chinese insulin market in 1994. 
By 2010, the company had grown its market 
share to 63 percent (about 13 percentage 
points higher than its global share) in what 
has become a $1 billion market. It has saved 
an estimated 140,000 life years in the process. 
Early engagement across all three levels of 
shared value has contributed to this success. 
The company has invested heavily in developing 
appropriate products that are well adapted to 
local needs. Its first local production facility 
opened in Tianjin in 1995, allowing it to gain 
production efficiencies and respond more 
quickly to market demand. In 2002, it was the 
first non-Chinese pharmaceutical company to 
establish an R&D center in China, which has 
allowed it to gain a competitive advantage 
through improved market understanding. In 
addition, the R&D center allows it to tap into a 
highly qualified talent pool of Chinese scientists, 
many of whom have returned from leading 
universities around the world to work in China.
Novo Nordisk has also invested in a broad 
range of cluster-strengthening initiatives. It 
worked with the World Diabetes Foundation 
(WDF), a nonprofit created and partly funded 
by the company, as well as with the Chinese 
government to develop and update national 
standard treatment guidelines. It has instituted 
a far-reaching physician-training program for 
diabetes diagnosis and care, both directly through 
its sales representatives and in partnership with 
the WDF and Chinese government. It has also 
pursued a high-profile awareness campaign 
to help improve patient management of the 
disease.
Beyond China, Novo Nordisk has identified 
a range of developing countries, including 
India, Bangladesh, and Nigeria, where a similar, 
comprehensive diabetes 
strategy may be viable. 
Finally, in China itself, it 
sees significant potential: 70 
percent of Chinese diabetics 
are still not diagnosed, and 
of those that are, just one 
in 10 successfully manages 
his or her condition. Changing these numbers 
holds enormous promise for both Chinese 
society and Novo Nordisk’s shareholders.
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Beyond China, Novo Nordisk has identified a range 
of developing countries, including India, Bangladesh, 
and Nigeria, where a similar, comprehensive diabetes 
strategy may be viable.
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Through its Developing Countries and Market 
Access business unit (DCMA), GlaxoSmithKline 
(GSK) is among the few companies researched 
for this report that are directly seeking to 
build a business in the world’s least developed 
countries (LDCs). DCMA was created in 2010 
and reports to the company’s Emerging Markets 
division. The group is still relatively small: It 
currently accounts for around 3 percent of 
total emerging markets revenues. However, it 
has ambitious expansion plans, owing to GSK’s 
competitive advantage in vaccines, antibiotics, 
and anti-infectives. The company intends to 
grow annual sales volumes from 60 million dose 
equivalents of these and other key products 
in 2010 to 300 million by 2015.
GSK has taken far-reaching 
actions to align its product 
portfolio with the realities of 
local markets, which suffer 
from weak infrastructure 
and limited ability to pay. 
The company is working to 
repackage or reformulate 
existing products — for example, packaging 
its Ventolin® asthma medication in one- or 
two-dose units that sell for a few cents each, 
rather than the 200-dose inhalers that sell for 
around $5 each in developed countries. Finally, 
the company is an industry leader in tiered 
pricing: It has committed to sell its patented 
products in LDCs for no more than 25 percent 
of the price in the U.K. and France. 
To support the delivery of targeted products, 
the company is adapting its value chain and 
making investments in the health clusters of 
LDCs. Local sales personnel are increasingly 
offered incentives based on volume, rather than 
incentives traditionally based on revenue. It is 
experimenting with risk-sharing agreements 
with distributors in several African countries. As 
new, lower-cost products are being rolled out, 
the company is working with its distributors to 
ensure that price reductions are passed on to 
patients. Also, GSK has committed to reinvest 
20 percent of the profits generated in LDCs 
into health systems and infrastructure, including 
clinics and training for health professionals. 
GSK’s DCMA business unit expects to contribute 
around $300M to the company’s top line in 2015. 
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GSK has taken far-reaching actions to align 
its product portfolio with the realities of local 
markets, which suffer from weak infrastructure 
and limited ability to pay.
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BRIDGING THE SHARED VALUE FRONTIER THROUGH CORPORATE 
PHILANTHROPY AND FUNDER INCENTIVES
Although shared value has the potential to address many 
global health needs, there will always be populations 
or locations that are beyond the reach of commercial 
approaches, where market failures exist. It is unlikely that 
the companies mentioned in this report will find pure 
commercial approaches for the underserved in locations like 
Haiti, Sierra Leone, or rural areas of Tanzania. Companies 
also find it difficult to invest in R&D for some neglected 
diseases, such as schistosomiasis or chagas disease. 
But, companies are exploring innovative ways to further 
expand opportunities in the shared value frontier — the 
area that borders market failure. Here, shared value 
opportunities are less viable in the short-term but 
can improve with the passing of time and economic 
progress. Due to low sophistication of demand for health 
services by patients or lack of health care infrastructure, 
companies may need to invest to a greater degree by 
innovating across multiple levels of shared value. In 
addition, companies are utilizing two methods — corporate 
philanthropic contributions and funder incentives — to 
overcome barriers and bridge the shared value frontier 
(see Figure 10).
In addition to more traditional philanthropy that has 
been ubiquitous within the health technology sector 
for decades, corporate philanthropy is now accelerating 
and incubating shared value. Likewise, governments and 
foundations recognize the health technology sector’s 
assets and expertise and are providing cash and in-kind 
incentives to unleash corporate R&D, marketing, and 
manufacturing resources for diseases and populations 
of the developing world. 
These types of bridging arrangements are relatively 
new. They mark new areas of opportunity for companies 
and global stakeholders to work together on product 
development, value chain enhancement, and local 
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cluster-building where there might not be immediate 
commercial rationale. 
Accelerating	and	Incubating	Shared	Value	
through	Corporate	Philanthropy
The pharmaceutical and medical device industries have 
given billions in charitable contributions, through cash 
and product donations, disaster relief, and ongoing health 
programs. Pharmaceutical companies, in particular, are 
among the largest corporate donors in the world: Merck’s 
total cash giving and product donations amounted to 
$1.16 billion in 2010.67 Companies featured in this report 
lead initiatives that leverage core assets, such as donated 
medicines and R&D expertise, through such programs 
as the Pfizer-supported International Trachoma Initiative 
and the GSK-supported Global Alliance to Eliminate 
Lymphatic Filariasis, to name a few. Companies have 
worked strategically in targeted countries — Abbott 
in Tanzania, Pfizer in Uganda, and Merck in Botswana. 
Such programs have reached millions of patients and 
provided care that would not otherwise have been 
delivered. They have also evolved, adding other funders 
to reduce dependency, codifying lessons, and focusing 
on capacity-building, particularly among government 
partners. 
But the role of corporate philanthropy in addressing global 
health challenges is changing even more profoundly as 
companies recognize philanthropy’s shortcomings and 
identify new shared value opportunities. Companies 
are now adopting a portfolio of corporate philanthropy 
approaches that are tailored to diseases and population 
groups. Where there are existing commercial interests, 
companies can accelerate shared value. In places where 
companies do not yet have commercial interests but may 
have in the longer-term future, they can incubate shared 
value. More traditional corporate philanthropy, in the form 
of product donations, volunteered time, and program 
support, will certainly continue for the poorest patients.
Companies accelerate shared value through corporate 
philanthropy by enabling the development of local clusters 
relevant to their business. When companies provide 
charitable support to local clusters, they can upgrade the 
capabilities of local health workers, increase demand for 
treatment, or even improve national guidelines for care. 
Eli Lilly’s NCD Partnership uses corporate-giving dollars 
to strengthen health systems in India, Brazil, South Africa, 
and Mexico. In two Indian cities, the company intends to 
increase the number of patients diagnosed with diabetes 
through mass media awareness campaigns and screening 
events. Nonprofit implementing partners will also train 
physicians, pharmacists, nurses, and community-based 
health care workers to improve diabetes care and 
treatment. Philanthropic investments that accelerate 
shared value integrate with other, more commercial, 
approaches and are intended to provide both societal 
and economic benefits. For Eli Lilly, the company has 
a strategic interest in growing its insulin business in a 
market that has one of the highest burdens of diabetes. 
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Companies also leverage their corporate philanthropy 
programs to incubate shared value opportunities in 
future markets or for diseases that have a longer time 
horizon for profitability. The Medtronic Foundation 
makes grants to organizations like Partners in Health to 
develop models for diagnosing and treating NCDs in less 
developed countries, such as Rwanda, where the company 
does not have a commercial presence. In this case, the 
Foundation acts independently but supports issues of 
future importance to the business, such as integrating 
NCDs into primary health care systems. 
By their nature, these corporate philanthropic investments 
are not company-specific, and competitors will also be 
lifted by the rising tide. The company taking the lead may 
reap differential benefits through capturing lessons or 
developing relationships. But this dynamic could make 
co-investment by multiple companies, even competing 
ones, feasible and desirable. For example, to support its 
strategic emphasis on NCDs in low- and middle-income 
countries, the Medtronic Foundation gave a $1 million 
grant to the NCD Alliance. Several other companies 
followed with additional funding. The Foundation is now 
funding multi-company initiatives to support frontline 
health workers in Southeast Asia and Africa and new 
medical school curricula for the next generation of 
global health leaders. 
The increasing focus on shared value is not a substitute 
for strategic forms of corporate philanthropy that address 
diseases, treat patients, or build health systems in locations 
that are the least developed. Patients in rural locations of 
Malawi or Tanzania do not have the financial resources to 
purchase medicines or devices, and health care systems 
are often non-existent. Companies can continue to focus 
on their greatest asset — the nonfinancial resources of 
expertise, networks, and influence — to advance these 
initiatives in partnership with local actors and with a 
sustainability strategy in place from the outset. 
Incentivizing	Shared	Value	through	Funder	
Collaboration
Governments, foundations, and multilateral organizations 
can accelerate movement along the shared value frontier 
through incentives to bridge market failures. Significant 
innovation has taken place over the last decade, with an 
emphasis on partnership incentives to spur corporate 
R&D for neglected diseases. Several approaches have 
emerged or are in an experimental phase: 
• International organizations like the GAVI Alliance have 
used Advanced Market Commitments (AMCs) to give 
vaccine manufacturers certainty that if they invest in 
development and achieve certain efficacy standards, 
they can be guaranteed a certain market volume and 
price. In the AMC for pneumococcal vaccines, for 
example, a $2.8 billion funding commitment led GSK 
and Pfizer to enter the market. They will now sell as 
many as 300 million doses each by 2023.68 
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• Prize mechanisms reward the development of technologies 
within a set of criteria. Today most are not at the 
scale necessary to influence major companies, but 
examples include the Tuberculosis Diagnostic X-Prize 
and the point-of-care fever diagnostic proposed by 
BIO Ventures for Global Health. 
• Product development partnerships (PDPs) are nonprofit 
organizations that build partnerships among private 
and government funders, 
companies, and academic 
institutions to reduce the 
financial risk of R&D for 
products used in low- and 
middle-income countries. 
To date, these efforts have 
been largely focused on the pharmaceutical rather 
than the medical device industry, with the Foundation 
for Innovative New Diagnostics (FIND) being the 
exception. A few successful products have launched, 
such as Coartem Dispersible, an artemisinin-based 
combination therapy (ACT) to fight malaria in children, 
developed by Novartis and Medicines for Malaria 
Ventures. Companies also dedicate specific R&D capacity 
to work with these nonprofit partners. GSK’s site at 
Tres Cantos in Spain, the Novartis Institute of Tropical 
Diseases in Singapore, and AstraZeneca’s Bangalore 
Research Institute are significant commitments of 
R&D capacity. As the shared value frontier advances, 
these investments may become powerful sources of 
future competitive advantage. 
• The FDA’s Priority Review Voucher program rewards 
companies for R&D focused on neglected diseases 
with a transferrable voucher that accelerates the 
review of another of the company’s products. The 
use of tax credits as a fiscal incentive is also being 
explored. Genzyme proposed a 50 percent credit on 
non-clinical expenses for neglected-diseases research 
to help take some risk out of R&D, although a recent 
analysis by Results for Development Institute calls for 
a more aggressive measure to create R&D incentives.69 
• To reduce the price of existing products, health 
organizations like UNITAID and BioVentures for 
Global Health have created patent pools (for HIV 
and neglected tropical diseases, respectively) that 
would license intellectual property rights to lower-cost 
manufacturers, giving originating companies a royalty 
and fostering greater competition. Other proposals, 
such as a Health Impact Fund, would compensate 
companies for the actual health improvements that 
their products create, strengthening the link between 
impact and business value.
Governments, foundations, and multilateral 
organizations can accelerate movement along 
the shared value frontier through incentives to 
bridge market failures.
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Implementing Shared Value  
in Global Health
Shared	value	represents	a	corporate-level	
strategic	choice	to	compete	on	the	basis	of	
serving	unmet	global	health	needs.	As	seen	
from	the	menu	of	approaches	featured	in	this	
report,	shared	value	holds	implications	for	
how	functions	across	the	company,	from	R&D	
to	marketing,	prioritize	their	investments	and	
activities.	
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Several companies interviewed for this paper have embarked on significant organizational change 
to implement shared value initiatives. While few have completed this process, five key principles 
guide their efforts (see Figure 11).
Focused	and	Determined	Leadership	at	the	CEO	and	Country	Levels
Almost every company interviewed for this paper spontaneously mentioned strong leadership 
as a key success factor. It is no coincidence that those firms that have been most successful in 
competing on the basis of meeting global health needs enjoy the energetic involvement of the 
CEO. GSK’s Sir Andrew Witty has articulated a corporate strategy to move beyond “white pills 
in Western markets,” and has been closely involved in the creation of that company’s Developing 
Countries and Market Access group. GE’s Jeffrey Immelt personally launched the firm’s healthy-
magination strategy; managers describe his role as key to engaging other business units in the 
strategy. 
In addition to strong direction from the corporate center, leadership is essential within individual 
country affiliates and business units, since shared value actually gets created at this level. While 
the support of Novartis CEO Joe Jimenez spurred the decision to establish a presence in rural 
India, it is the dedicated work of Anuj Pasrija, head of Novartis’ Social Business Group, and his 
team that built the company’s Arogya Parivar business.
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The experience of Eli Lilly and Company 
demonstrates how a company new to shared 
value needs to invest up front in strategy 
development and in aligning internal operations.
Lilly had a strong history of philanthropic 
contributions, first in areas relatively separate 
from its core business, such as education, and 
later through more aligned commitments like 
the Lilly MDR-TB Partnership, which included 
technology transfers and anti-tuberculosis 
drug licensing. Simultaneously, the company 
prioritized emerging-markets growth. A 2009 
restructuring elevated the importance of the 
emerging-markets business unit, and countries 
like India have goals of tripling revenue in the 
next five years. Given the business targets, the 
company needed its engagement on global 
health issues to evolve as well. 
As an entry point into shared value, the company 
launched the Lilly NCD Partnership, an effort 
to improve diabetes care in key low- and 
middle-income countries. The partnership will 
strengthen local clusters immediately, benefiting 
the company and people with diabetes, as 
well as generating longer-term knowledge 
through research. 
In developing the initiative, the company 
encountered several implementation challenges. 
When Lilly staff had previously considered 
opportunities to reinvent the company’s 
involvement in diabetes care in new markets, 
they found themselves going against the grain 
of conventional thinking about the company’s 
contribution to society — specifically, that 
social engagement should be separate from 
the business. As senior leaders in the company 
developed a deeper understanding of the 
potential to create shared value, the idea of a 
more aligned approach gained traction. But it 
took deep engagement and leadership from 
the head of corporate affairs, to the diabetes 
and emerging markets business units and up 
to the CEO, to achieve this shift.
The company also needed to balance central 
strategies with country ownership: The initiative 
is being launched in India, South Africa, Mexico, 
and Brazil, all countries where Lilly has a strong 
local presence. This local involvement meant 
balancing central strategic coherence from 
headquarters with the specific local situations, 
relationships, and opportunities that the local 
affiliate presented — and also required substantial 
time for sharing ideas and gaining alignment.
The development of the initiative took more than 
a year of planning, but Lilly leaders emphasize 
how crucial that up-front investment was to 
overcome the challenges of shifting to a new 
strategy.
Eli Lilly & Co.: 
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A	Culture	of	Innovation	and	Learning	Reflected	in	Structures	and	Incentives
Innovation and learning is essential to creating shared value in global health. Without a culture 
that embraces entrepreneurial risk-taking, companies may miss opportunities to reach under-
served populations in new ways, only to see those opportunities seized by bolder competitors. 
Corporations can build such a culture by adopting structures that offer managers the autonomy 
and authority to innovate while promoting firm-wide learning, and by aligning incentives with 
long-term value creation.
Two organizational models for promoting a culture of innovation and learning are emerging. A 
number of companies have established a cross-functional team with a mandate to expand efforts 
company-wide. Typically these units function as coordinators, informing how other parts of the 
company implement strategies. GE’s healthymagination initiative serves as a central node for 
innovations to expand access, decrease cost, and improve quality — but product managers within 
other GE business units or outside partners administer product R&D. At BD, a global health team 
develops partnerships and identifies product opportunities related to health needs in the least 
developed countries, but ultimately other business units execute on these ideas. For some compa-
nies, such as Medtronic in its work on NCDs, these coordinating bodies are also a mechanism for 
engaging the corporate foundation while ultimately keeping core responsibilities on the business 
side.
A second model for organizing to create shared value is a separate innovation unit that directly 
manages initiatives, usually in conjunction with country affiliates. Several leading companies 
have created walled-off units charged with developing innovative strategies to reach new markets. 
Novartis, for example, manages Arogya Parivar through a separate Social Business Group, rather 
than through its Indian affiliate. This approach provides room for Novartis to experiment, without 
affecting operating structures or incentives in other parts of the Indian business. GSK’s Devel-
oping Countries and Market Access group represents a similar implementation approach. Such 
dedicated business units create space to innovate around shared value, free from short-term sales 
pressures that could undermine efforts to reach new customer segments. They also help to ensure 
a stable base of resources for investment in shared value initiatives.
Financial and non-financial performance incentives also have an important influence on 
managers’ ability and willingness to focus on solving new health challenges. For example, several 
companies interviewed reported that, traditionally, professional success hinges on achieving 
measurable results during a two- to three-year management rotation. These incentive patterns can 
make it difficult for managers to find and pursue shared value opportunities that may take longer to 
demonstrate a return on investment. Now, companies are starting to create new systems that align 
individuals’ incentive structures with elements important for shared value. In many cases, this has 
shifted incentives from margins to volumes as the primary metric of success.
2 >
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New	Approaches	to	Measurement	that	Track	the	Link	between	Business	Value	and	
Patient	Lives	Improved
Innovation and learning depend on measurement that captures the link between economic value 
creation for the business and improved health outcomes for patients. An understanding of what 
works allows companies to assess the potential of new investments to create shared value, and 
provides a basis to allocate resources and set incentives.
Several companies are leading the way in measuring their work. GE works with the consultancy 
Oxford Analytica to assess the cost, quality, and access implications of its product innovation. The 
assessment considers factors like the marginal improvement in diagnosis accuracy rates, as well as 
the cost savings for a local health system if better diagnosis results in more streamlined treatment. 
On the business side, product managers assess sales potential in the same way they would evaluate 
any GE Healthcare product, although with hurdles that use adjusted rates of return in some cases. 
To date the process has resulted in 45 products that are attractive business opportunities for GE 
and achieve healthymagination’s goals of 15 percent improvements on cost, quality, and access. 
Novo Nordisk has calculated a net present value for itself, and for Chinese society, of better disease 
management in diabetic patients. The company calculates that improving patient control over 
diabetes — through better diagnosis, appropriate treatment, and ongoing disease management — is 
worth around $2,350 to Chinese society over the lifetime of a patient in an urban area. It is also 
worth around $3,400 per patient to Novo Nordisk in increased treatment sales. If China could help 
the estimated 16 million people with diabetes in large urban centers to exercise greater control 
over their disease, it could have a net present value of some $37 billion to the country. Moreover, if 
Novo Nordisk were able to maintain around a 60 percent market share, such an improvement could 
have a net present value of as much as $30 billion to the company.71
These metrics allow Novo Nordisk to allocate resources based on an informed expectation of 
potential returns. The company also tracks the contribution of specific initiatives toward achieving 
overarching goals, in order to adapt and improve its efforts. For example, the company discovered 
that training physicians in small cities had a 9 percent greater effect on treatment management 
than training their counterparts in larger cities.
New	Skills	in	Identifying	and	Acting	on	Unmet	Health	Needs		 	
To implement shared value strategies, many companies are changing how they define responsi-
bilities and hire for roles, emphasizing hybrid backgrounds and skills. In addition to managing 
sophisticated commercial operations, country managers are often expected to be thought leaders 
on health needs in their respective countries. 
Companies are also investing in the professional development of existing staff. Novartis and GSK 
both use leadership-development programs to create opportunities for promising talent to spend 
4 >
3 >
45Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
BD (Becton, Dickinson and Co.) is an example 
of how a company starting from an evaluation 
of unmet health needs and philanthropic 
involvement in global health can expand to a 
more holistic shared value strategy. 
BD has engaged in a range of public-private 
sector collaborations on global health issues. 
HIV was a particular area of focus: BD engaged 
with the US President’s Emergency Plan for 
AIDS Relief (PEPFAR) on issues like laboratory-
capacity strengthening and safer blood collection, 
and with the Clinton Health Access Initiative to 
expand access to CD4 diagnostic testing. BD 
entered into these agreements from a socially 
motivated commitment to global health, and 
leaders stress the importance of authenticity 
of purpose, integrity, and trust-building in 
forming collaborations. What makes the BD 
experience different from traditional corporate 
social responsibility is how the company learned 
from these experiences to identify opportunities 
for market expansion and product innovation, 
allowing it to further advance global health 
outcomes while also generating substantial 
business value. 
As the company assessed the landscape of 
infectious disease in Sub-Saharan Africa in the 
early 2000s, it identified product and training 
needs vital to supporting the global response 
to HIV/AIDS. Areas of focus included laboratory 
system strengthening, safe immunizations of 
children, access to diagnostic testing in district 
and rural settings, and safe blood handling. 
These efforts led to the creation of collaborative 
programs and tailored product engineering. 
Developing a firsthand understanding of the 
gaps in existing health systems helped the 
company pursue new program- and product-
development activities to serve unmet needs. 
Its new products would ultimately be relevant 
not only to the sites of their public-private 
collaborations in Africa, but also to a more 
global market. 
An intentional structure and process enabled 
these opportunities. A Global Health group 
coordinates company involvement in these issues 
and collaborates directly with BD’s product 
teams. Ultimately, the process of committing 
the company’s resources to fulfill broad social 
needs has infused a “new management science” 
into the company as a whole. Its operating 
model of deep involvement in public-private 
sector collaborations in countries like Kenya 
and Zambia is now informing how the company 
engages to address health needs in China and 
other low- and middle-income countries. 
BD: 
Learning From 
Unmet Health 
Needs72
COMPANY PROFILE
time thinking creatively about strategic problems associated with serving low- and middle-income 
countries. A significant number of pharmaceutical firms, including Pfizer, Abbott, Eli Lilly, and 
GSK, have well-known skill-based volunteering programs in low- and middle-income countries 
that have a similar sensitizing and experiential learning effect on employees.
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New	Partnerships	for	Shared	Value	Insights	and	Implementation
Health technology companies have had a long history of engaging with organizations that set the 
context for global health. As mentioned earlier, various stakeholders have communicated expec-
tations for the sector in terms of R&D priorities, access to medicines, and intellectual property. 
Low- and middle-income country governments create or foster the policy, regulatory, and health 
system environments. Organizations like WHO, Oxfam, and MSF continue to exert major influence 
in global health policy. Likewise, as mentioned above (see “Bridging the Shared Value Frontier”), 
external funders have also played an important role in providing incentives to stimulate companies 
to act in ways that might not otherwise be in their short-term commercial interest. Two new types 
of partners are appearing as shared value initiatives gain momentum: insight and information 
providers and implementation partners. 
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Figure 12: Roles of Shared Value Stakeholders
Role  Description  Examples
Context Setting 
Organizations
• Shape the environment within 
which companies operate, including 
regulation, guidelines, health 
system organization, norms and 
expectations
• Local governments
• Coordinating authorities
• Regulatory entities
• Advocacy organizations
• Industry associations
• Investment analysts
Information & Insight 
Providers
• Conduct market research and 
analysis, or offer advice and 
expertise, to provide information and 
insights that industry has difficulty 
accessing
• Nonprofit organizations
• Global health consulting firms
Implementation 
Partners
• Work directly on the development 
or delivery of products, services, 
or other investments, to provide 
implementation capabilities that 
companies lack
• Nonprofit organizations
• Product development partnerships
• Industry competitors
• Local health systems
Funders • Provide overseas development aid 
and philanthropic funds to bridge 
market failures in global health
• Foundations
• Multinationals
• Governments
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Two	new	types	of	partners	are	appearing	as	shared	value	
initiatives	gain	momentum:	insight	and	information	providers	and	
implementation	partners.	
Information and insight providers play a vital role in helping companies develop and execute 
shared value strategies. They plug gaps in knowledge, expertise, and insight. Groups like the Access 
to Medicine Foundation, IMS Health, Broadreach, Axios, and IDEO support companies as they 
analyze new-product opportunities, design access approaches, and assess the strength of the 
surrounding health system.
Implementation partners work with companies across all three levels of shared value, as shown 
in the examples featured below:
  Reconceiving products and markets: The nonprofit organization PATH has for years part-
nered with companies on R&D to address diseases in the developing world. Increasingly, the 
organization looks for alignment with companies’ business interests when establishing part-
nerships. For example, it saw a clear market for a low-cost Japanese encephalitis vaccine, but 
needed a producer to work with. Chengdu Institute of Biological Products, a Chinese manu-
facturer, wanted to enter the more lucrative export market, but needed technical assistance to 
meet international quality standards. PATH was an effective partner since it understood the 
company’s business drivers, and now the company is selling 135 million doses of vaccine to the 
Indian government at affordable prices. Companies are also forming partnerships with other 
companies, such as the agreement between Tibotec and Gilead to develop and commercialize a 
new once-daily, single-tablet, fixed-dose antiretroviral combination product that uses Tibotec’s 
Prezista and Gilead’s Cobicistat products. 
  Redefining productivity in the value chain: The Clinton Health Access Initiative (CHAI) works 
with manufacturers of antiretrovirals, antimalarials, diagnostics, and other health technolo-
gies to help companies reduce production costs. By focusing on efficiency improvements, cost 
reductions for active pharmaceutical ingredients, and the predictability of demand, CHAI has 
facilitated dramatic price reductions of these technologies, particularly with HIV treatments, 
while creating business opportunities for companies. In another example, the for-profit firm 
Moksha8 partners with pharmaceutical companies to market and distribute products in Latin 
America in exchange for a percentage of sales. Its model pursues a higher-volume approach for 
drugs facing generic competition, which traditional pharmaceutical strategies might see as no 
longer viable. With Pfizer’s antibiotic Vibramycin, for example, the partnership led to 40 percent 
greater sales than Pfizer’s projections.73 
  Enabling local cluster development: Novartis started SMS for Life, an initiative that uses 
mobile phones and SMS technology to manage the supply of artemisinin-based combina-
tion therapies and quinine injectables to reduce stock-outs, in conjunction with the Roll Back 
Malaria Partnership, IBM, Vodafone, and the Ministry of Health in Tanzania. The successful 
Tanzania pilot has led to current efforts to scale the model in other countries. 
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Catalyzing Greater Shared Value  
for Global Health 
Creating	shared	value	is	not	a	panacea	for	all	
global	health	challenges.	Some	efforts	will	
inevitably	disappoint,	and	market	failures	
will	remain.	Nevertheless,	pharmaceutical	
and	medical	device	companies	have	an	
extraordinary	opportunity	to	help	reduce	
global	suffering	and	ill-health	by	building	
a	competitive	advantage	in	the	low-	and	
middle-income	countries	that	will	underpin	
future	industry	growth.
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This study has charted the shared value journey of health technology companies for the benefit 
of business and global health. But the movement is just beginning, as both industries still focus 
their attention on premium markets in North America, Europe, and Japan.  Significant barriers, 
including corporate mindsets and challenging environments in low- and middle-income countries, 
are slowing greater investments in shared value initiatives. The following recommendations for 
companies and stakeholders can catalyze greater experimentation in shared value for the benefit of 
companies, patients, and health systems.
Recommendations	for	Companies	
Shift from defensive to affirmative engagement with patients in low- and middle- 
income countries.	
Companies should be transparent with global stakeholders about their ambitions in low- and 
middle-income countries. Specific shared value approaches, motivated by profit, can be articulated 
for the benefit of the global health field. Where shared value approaches are not presently feasible, 
companies can explain the role of their philanthropic contributions and the intentions of partner-
ships with government and private funders. These clarifications are important as global health 
stakeholders are often confused about the motivations of companies in low- and middle-income 
countries and how the various activities — commercial, philanthropic, or incentivized partner-
ships — fit within their overall corporate strategies. Likewise, companies are not always clear as 
to what constitutes appropriate types of investments for fear of appearing to make a profit from 
underserved patients. 
More affirmative shared value positions can change the present dynamic of stakeholder engage-
ment. All the companies mentioned in this report have elaborate global stakeholder engagement 
systems that require time and effort to manage. Stakeholder engagement should evolve to include 
candid dialogue about what is and is not possible to serve underserved patients. Stakeholders can 
be a source of proactive learning about patient needs and health system requirements, rather than 
targets for public relations messages. 
Industry associations, such as the Pharmaceutical Research and Manufacturers of America 
(PhRMA), the International Federation of Pharmaceutical Manufacturers & Associations 
(IFPMA), and the Advanced Medical Technology Association (AdvaMed) can be helpful in driving 
more authentic partnerships with stakeholders. While the tone is changing, these associations still 
tend to view company partnerships through the lens of philanthropy and reputation. Instead, they 
should be trumpeting the shared value initiatives of leading companies, thereby accelerating the 
trend. 
→
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Innovate and capture knowledge on health product delivery. 
As companies learn more about how to meet the needs of hard-to-reach, poorly served populations, 
lessons should be shared, within the limits of competitive confidentiality. Companies should work 
with stakeholders to create a catalog of case studies, since the delivery of health products is critical 
for them, too. 
R&D portfolio management processes are elaborate, structured, measurable, and standardized. 
The same cannot be said for the delivery of health technologies to underserved populations in 
low- and middle-income countries. Although many are experimenting, few companies, or other 
global health actors, for that matter, have a deep understanding of what it takes to deliver drugs 
and medical devices into resource-constrained settings. Even fewer understand how to do this in 
multiple country settings.74 
A good model for emerging knowledge on the subject is the International Partnership for Innova-
tive Healthcare Delivery, led by Duke Medicine, McKinsey, the World Economic Forum, and a 
handful of pharmaceutical and medical device companies.75 The initiative is actively assessing and 
promoting health product delivery models employed by the private, public, and nonprofit sectors. 
Initiatives like the Global Health Delivery Project, a partnership among the Harvard School 
of Public Health, Harvard Business School, Harvard Medical School, and Brigham & Women’s 
Hospital, could be additional sponsors or repositories of knowledge on private sector-driven health 
care delivery. 76
Experiment with shared value measurement to spur learning and innovation.
Pharmaceutical and medical device companies should be in a position to lead other industries on 
measuring shared value, due to the inherent alignment between the increased sales of their prod-
ucts and improved health. Measurement allows companies to show how they make money as they 
reduce the burden of disease. Such metrics could ignite a cascade of reinforcing benefits, as compa-
nies more quickly move beyond their saturated markets, deepen knowledge about new patients, 
and develop appropriate shared value strategies to meet the special needs of patient segments. 
Companies can start measuring health impact in modest, exploratory ways. Companies should set 
specific, forward-looking targets for populations, behavior changes, health system strengthening 
and disease indicators, and should measure progress toward them. 
While companies can experiment individually, the best path may be a consortium of companies 
that cooperate on a framework for measurement. While such cooperation is rare in the health 
technology sector, the results would benefit each company and establish the pharmaceutical and 
medical device industries as partners in global health. 
→
→
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Investors are a key consumer of such information. Measurement of shared value will shine more 
light on new markets for investors, increasing their understanding and appreciation for the activi-
ties highlighted in this report. 
Invest early to gain first-mover advantage.
Making shared value investments is difficult and risky, and returns may take time to accrue. Novo 
Nordisk spent a decade building its presence in China, but has been rewarded with a market share 
of more than twice its nearest competitor. Similarly, GSK’s strong market position in India stems 
in part from having been in the market since the 1920s, in addition to its relevant product portfolio. 
Sanofi-Aventis enjoys similar legacy advantages in West Africa. Those companies that invest early 
will, therefore, likely find themselves with a sizable competitive advantage as new markets develop 
and mature.
Recommendations	for	Global	Health	Stakeholders	
 → Context-Setting entities need to monitor the evolution toward shared value. Specifically, 
advocacy-oriented organizations have a role to play in ensuring that health technology compa-
nies develop strategies to expand access to poorer patients at the frontier of shared value in 
Africa and Asia. Governments can reach out to companies to complement the public sector’s 
role in health care provision. 
 → Information and Insight Providers can stimulate more immediate shared value opportuni-
ties through patient research, value chain analysis, and health system auditing. The Access to 
Medicine Index, for example, can add more business results metrics like product volumes sold, 
as well as case studies that show how companies are addressing the barriers mentioned in this 
report. 
 → Implementation Partners can be more proactive in offering their services to companies. The 
product-development and cluster-building services of PATH, Population Services Interna-
tional, and CARE are relatively new to pharmaceutical and medical device companies. For the 
most part, these organizations are still viewed as philanthropic grantees rather than value-
added partners in shared value initiatives.
 → Funders like the Bill & Melinda Gates Foundation, the UK Department for International 
Development, and others have supported R&D partnerships to bridge the shared value fron-
tier. In comparison to R&D, fewer incentives exist to spur company involvement in the actual 
delivery of products. As companies expand their reach among poor populations in low- and 
middle-income countries, opportunities may exist to incentivize the private sector to scale-up 
delivery. 
→
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Conclusion
Creating shared value is not a panacea for all global health challenges. 
Some efforts will inevitably disappoint, and market failures will remain. 
Nevertheless, pharmaceutical and medical device companies have an 
extraordinary opportunity to help reduce global suffering and ill-health by 
building a competitive advantage in the low- and middle-income countries 
that will underpin future industry growth. Firms that engage in this area can 
become engines of progress for the global health field. They can be engaged 
partners rather than neutral suppliers. We hope this report serves to illustrate 
the scale of that opportunity, and triggers discussion and innovation around 
ways to capitalize on it.
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